Chen Chen, Guo Yuying, Guo Yaxin, Wu Xiaoke, Si Chaohua, Xu Yanxin, Kang Qiaozhen, Sun Zhenqiang
Department of Colorectal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
School of Life Science, Zhengzhou University, Zhengzhou, China.
Front Oncol. 2021 Oct 20;11:746789. doi: 10.3389/fonc.2021.746789. eCollection 2021.
Cancer drug resistance has always been a major difficulty in cancer therapy. In the face of drug pressure, resistant cancer cells show complex molecular mechanisms including epigenetic changes to maintain survival. Studies prove that cancer cells exhibit abnormal m6A modification after acquiring drug resistance. m6A modification in the target RNA including non-coding RNA can be a controller to determine the fate and metabolism of RNA by regulating their stability, subcellular localization, or translation. In particular, m6A-modified non-coding RNA plays multiple roles in multiple drug-resistant cancer cells, which can be a target for cancer drug resistance. Here, we provide an overview of the complex regulatory mechanisms of m6A-modified non-coding RNA in cancer drug resistance, and we discuss its potential value and challenges in clinical applications.
癌症耐药性一直是癌症治疗中的一大难题。面对药物压力，耐药癌细胞表现出复杂的分子机制，包括表观遗传变化以维持生存。研究证明，癌细胞在获得耐药性后会出现异常的m6A修饰。靶RNA（包括非编码RNA）中的m6A修饰可以通过调节其稳定性、亚细胞定位或翻译来决定RNA的命运和代谢，从而发挥调控作用。特别是，m6A修饰的非编码RNA在多药耐药癌细胞中发挥多种作用，可能成为癌症耐药性的一个靶点。在此，我们概述了m6A修饰的非编码RNA在癌症耐药性中的复杂调控机制，并讨论了其在临床应用中的潜在价值和挑战。
